Ownership of Patent Rights. Licensor represents and warrants that, as of the Effective Date, it possesses the exclusive right, title, and interest in and to the Patent Rights and that it has the full legal right and power to enter into the obligations and grant the rights and licenses set forth in this Agreement.
Ownership of Patent Rights. LGLS represents and warrants that (a) it is the sole owner of all right, title and interest in and to the LGLS Patent Rights and it Controls the LGLS Know-How, (b) it has not granted any license under the LGLS Patent Rights to any Third Party and is under no obligation to grant any such license, except to Anadys, and (c) there are no outstanding liens, encumbrances, agreements or understandings of any kind, either written, oral or implied, regarding the LGLS Patent Rights or the LGLS Know-How which are materially inconsistent or are materially in conflict with this Agreement.
Ownership of Patent Rights. Title to inventions, discoveries, improvements and other technology, whether or not patentable (collectively, “Inventions”), and any patent or patent application claiming such Inventions, shall be as set forth below. Inventorship shall be determined under the patent laws of the country in which the relevant patent application was filed.
Ownership of Patent Rights. Patent Rights claiming such inventions. All inventions invented jointly by employees or agents of SIGNAL and DPM or their respective Affiliates in connection with the Collaboration, and all Patent Rights claiming such inventions shall be owned jointly by DPM and SIGNAL as Collaboration Patents Rights. Inventorship shall be determined under U.S. patent law.
Ownership of Patent Rights. Ownership of inventions conceived of or reduced to practice in the course of the Collaboration shall be determined in accordance with the rules of inventorship under United States patent law. Ethicon shall own all inventions conceived of and reduced to practice solely by its employees and agents, and all patent applications and patents claiming such inventions. Genetronics shall own all Genetronics Technology and all inventions conceived of and reduced to practice solely by its employees and agents, and all patent applications and patents claiming such inventions. All inventions conceived of and reduced to practice jointly by employees or agents of Genetronics and employees or agents of Ethicon, and all Joint Patent Rights shall be owned jointly by Genetronics and Ethicon.
Ownership of Patent Rights. Pieris is the exclusive owner of all right, title and interest in, or is the exclusive licensee, with the right to sublicense in the Field and in the Territory of, the Patent Rights related to Pieris IP.
Ownership of Patent Rights. […***…]represents and warrants, as of the Effective Date, that it is the exclusive owner of all right, title and interest in, or is the exclusive licensee of, the […***…].
Ownership of Patent Rights. C4T is the exclusive owner of all right, title and interest in, or is the exclusive licensee of, the C4T Base Patent Rights. Appendix 1.5 contains a complete and accurate list of all patents and patent applications included in the C4T Base Patent Rights.
Ownership of Patent Rights. As of the Effective Date and the Restatement Date, FMI warrants and represents that it is the exclusive owner of all right, title and interest in, or is the exclusive licensee of, the FMI Patent Rights in the Territory relating to the use, sale, offer for sale, import, or export of the Products in the Territory.
Ownership of Patent Rights. Eleven is the exclusive owner of all right, title and interest in, or is the exclusive licensee of, the Eleven Base Patent Rights existing on the Signature Date. Appendix 1.30 and Appendix 13.2 collectively contain a complete and accurate list of all Patent Rights Controlled by Eleven as of the Signature Date that Cover Eleven Compounds. Between the Signature Date and the Effective Date, Eleven will have used Commercially Reasonable Efforts to prosecute or maintain the Core Patent Rights and has not granted and will not grant rights to any Third Party under the Eleven Base Patent Rights that conflict with the rights granted to Roche hereunder.
